So, I'm here to share this information with you
Studies examining body composition changes during GLP-1 therapy, including the STEP trials (semaglutide) and SURMOUNT-1 (tirzepatide), have demonstrated that approximately 2540% of total weight lost may come from lean body mass, including skeletal muscle, rather than exclusively from fat mass
Unfortunately, ingredients and doses lose their luster after that
Liraglutide then became available, and several other GLP-1 analogs are in development
For best preservation, store at 4C or colder away from bright light
Attention Deficit Hyperactivity Disorder The safety data in this section is based on data from the 4-week controlled parallel-group clinical studies of VYVANSE in pediatric and adult patients with ADHD [see Clinical Studies (14.1)]